Cargando…

Effects of novel Fufang Biejia Ruangan Tablets with sheep placenta as substitute for Hominis Placenta on CCl(4)-induced liver fibrosis

OBJECTIVE: Fufang Biejia Ruangan Tablet (FBRT) is widely used for the treatment of liver fibrosis. However, Hominis Placenta (HP), as an important adjuvant of FBRT, has been restricted for medicinal using due to the limited availability, ethical controversy and safety issues. The present study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Baode, Deng, Li, Liu, Yuan, Li, Ruisheng, Shen, Chengying, Liu, Xiao, Li, Yinchao, Yuan, Hailong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476806/
https://www.ncbi.nlm.nih.gov/pubmed/36120135
http://dx.doi.org/10.1016/j.chmed.2021.09.013
_version_ 1784790219469357056
author Shen, Baode
Deng, Li
Liu, Yuan
Li, Ruisheng
Shen, Chengying
Liu, Xiao
Li, Yinchao
Yuan, Hailong
author_facet Shen, Baode
Deng, Li
Liu, Yuan
Li, Ruisheng
Shen, Chengying
Liu, Xiao
Li, Yinchao
Yuan, Hailong
author_sort Shen, Baode
collection PubMed
description OBJECTIVE: Fufang Biejia Ruangan Tablet (FBRT) is widely used for the treatment of liver fibrosis. However, Hominis Placenta (HP), as an important adjuvant of FBRT, has been restricted for medicinal using due to the limited availability, ethical controversy and safety issues. The present study aimed to investigate the therapeutic effects of novel FBRT (N-FBRT) with sheep placenta (SP) as substitute for HP on liver fibrosis and explore its possible mechanisms. Different dosages of SP in N-FBRT were also evaluated. METHODS: Rats were subcutaneously injected with CCl(4) to induce liver fibrosis and then treated with N-FBRT and FBRT. The anti-hepatic fibrosis effect was determined based on biomarkers analysis of liver function and hepatic fibrosis, and the liver pathology was visualized by H&E staining and Masson staining. The oxidative stress and inflammatory cytokines were also detected. Immunohistochemical staining of α-SMA, real time PCR and Western blotting were performed to evaluate hepatic stellate cells (HSCs) activation and TGF-β1/Smad signaling pathway. RESULTS: N-FBRT and FBRT could ameliorate CCl(4)-induced liver fibrosis and improve liver function, as evidenced by lowering serum biomarkers levels of liver function and hepatic fibrosis, and decreasing hepatic Hyp content and collagen deposition, and improving the hepatic morphology and architecture changes. Moreover, the anti-liver fibrosis effect was better when the dosage of SP used in N-FBRT was 1/2 of HP in FBRT. Administration of N-FBRT markedly alleviated oxidative stress and inflammatory cytokines, and inhibited α-SMA expression. Furthermore, the mRNA expression of Col I, Col III, α-SMA and TGF-β1, and proteins expression of α-SMA, TGF-β1, Smad2/3 and p-Smad2/3 were significantly down-regulated by N-FBRT treatment. CONCLUSION: SP can be used as substitute for HP to prepare N-FBRT for the treatment of liver fibrosis and the anti-liver fibrosis effect of N-FBRT is achieved by eliminating oxidative stress and inflammation, and inhibiting HSCs activation and ECM production by blocking TGF-β1/Smad signaling pathway.
format Online
Article
Text
id pubmed-9476806
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94768062022-09-16 Effects of novel Fufang Biejia Ruangan Tablets with sheep placenta as substitute for Hominis Placenta on CCl(4)-induced liver fibrosis Shen, Baode Deng, Li Liu, Yuan Li, Ruisheng Shen, Chengying Liu, Xiao Li, Yinchao Yuan, Hailong Chin Herb Med Original Article OBJECTIVE: Fufang Biejia Ruangan Tablet (FBRT) is widely used for the treatment of liver fibrosis. However, Hominis Placenta (HP), as an important adjuvant of FBRT, has been restricted for medicinal using due to the limited availability, ethical controversy and safety issues. The present study aimed to investigate the therapeutic effects of novel FBRT (N-FBRT) with sheep placenta (SP) as substitute for HP on liver fibrosis and explore its possible mechanisms. Different dosages of SP in N-FBRT were also evaluated. METHODS: Rats were subcutaneously injected with CCl(4) to induce liver fibrosis and then treated with N-FBRT and FBRT. The anti-hepatic fibrosis effect was determined based on biomarkers analysis of liver function and hepatic fibrosis, and the liver pathology was visualized by H&E staining and Masson staining. The oxidative stress and inflammatory cytokines were also detected. Immunohistochemical staining of α-SMA, real time PCR and Western blotting were performed to evaluate hepatic stellate cells (HSCs) activation and TGF-β1/Smad signaling pathway. RESULTS: N-FBRT and FBRT could ameliorate CCl(4)-induced liver fibrosis and improve liver function, as evidenced by lowering serum biomarkers levels of liver function and hepatic fibrosis, and decreasing hepatic Hyp content and collagen deposition, and improving the hepatic morphology and architecture changes. Moreover, the anti-liver fibrosis effect was better when the dosage of SP used in N-FBRT was 1/2 of HP in FBRT. Administration of N-FBRT markedly alleviated oxidative stress and inflammatory cytokines, and inhibited α-SMA expression. Furthermore, the mRNA expression of Col I, Col III, α-SMA and TGF-β1, and proteins expression of α-SMA, TGF-β1, Smad2/3 and p-Smad2/3 were significantly down-regulated by N-FBRT treatment. CONCLUSION: SP can be used as substitute for HP to prepare N-FBRT for the treatment of liver fibrosis and the anti-liver fibrosis effect of N-FBRT is achieved by eliminating oxidative stress and inflammation, and inhibiting HSCs activation and ECM production by blocking TGF-β1/Smad signaling pathway. Elsevier 2021-12-21 /pmc/articles/PMC9476806/ /pubmed/36120135 http://dx.doi.org/10.1016/j.chmed.2021.09.013 Text en © 2021 Tianjin Press of Chinese Herbal Medicines. Published by ELSEVIER B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Shen, Baode
Deng, Li
Liu, Yuan
Li, Ruisheng
Shen, Chengying
Liu, Xiao
Li, Yinchao
Yuan, Hailong
Effects of novel Fufang Biejia Ruangan Tablets with sheep placenta as substitute for Hominis Placenta on CCl(4)-induced liver fibrosis
title Effects of novel Fufang Biejia Ruangan Tablets with sheep placenta as substitute for Hominis Placenta on CCl(4)-induced liver fibrosis
title_full Effects of novel Fufang Biejia Ruangan Tablets with sheep placenta as substitute for Hominis Placenta on CCl(4)-induced liver fibrosis
title_fullStr Effects of novel Fufang Biejia Ruangan Tablets with sheep placenta as substitute for Hominis Placenta on CCl(4)-induced liver fibrosis
title_full_unstemmed Effects of novel Fufang Biejia Ruangan Tablets with sheep placenta as substitute for Hominis Placenta on CCl(4)-induced liver fibrosis
title_short Effects of novel Fufang Biejia Ruangan Tablets with sheep placenta as substitute for Hominis Placenta on CCl(4)-induced liver fibrosis
title_sort effects of novel fufang biejia ruangan tablets with sheep placenta as substitute for hominis placenta on ccl(4)-induced liver fibrosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476806/
https://www.ncbi.nlm.nih.gov/pubmed/36120135
http://dx.doi.org/10.1016/j.chmed.2021.09.013
work_keys_str_mv AT shenbaode effectsofnovelfufangbiejiaruangantabletswithsheepplacentaassubstituteforhominisplacentaonccl4inducedliverfibrosis
AT dengli effectsofnovelfufangbiejiaruangantabletswithsheepplacentaassubstituteforhominisplacentaonccl4inducedliverfibrosis
AT liuyuan effectsofnovelfufangbiejiaruangantabletswithsheepplacentaassubstituteforhominisplacentaonccl4inducedliverfibrosis
AT liruisheng effectsofnovelfufangbiejiaruangantabletswithsheepplacentaassubstituteforhominisplacentaonccl4inducedliverfibrosis
AT shenchengying effectsofnovelfufangbiejiaruangantabletswithsheepplacentaassubstituteforhominisplacentaonccl4inducedliverfibrosis
AT liuxiao effectsofnovelfufangbiejiaruangantabletswithsheepplacentaassubstituteforhominisplacentaonccl4inducedliverfibrosis
AT liyinchao effectsofnovelfufangbiejiaruangantabletswithsheepplacentaassubstituteforhominisplacentaonccl4inducedliverfibrosis
AT yuanhailong effectsofnovelfufangbiejiaruangantabletswithsheepplacentaassubstituteforhominisplacentaonccl4inducedliverfibrosis